United States v. Scully

877 F.3d 464
CourtCourt of Appeals for the Second Circuit
DecidedDecember 13, 2017
DocketDocket 16-3073-cr
StatusPublished
Cited by35 cases

This text of 877 F.3d 464 (United States v. Scully) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Scully, 877 F.3d 464 (2d Cir. 2017).

Opinion

GERARD E. LYNCH, Circuit Judge:

William Scully appeals from a judgment of conviction entered following a five-week jury trial in the United States District Court for the Eastern District of New York (Arthur D. Spatt, Judge).

The jury found Scully guilty of mail and wire fraud and conspiracy to commit the same in violation of 18 U.S.C. §§ 1341, 1343, and 1349; conspiracy to defraud the United States through the introduction of misbranded drugs into interstate commerce in violation of 18 U.S.C. § 371; introduction of misbranded drugs into interstate commerce in violation of 21 U.S.C. §§ 331(a) and 333(a)(2); receipt of mis-branded drugs into interstate commerce and delivery thereof for pay in violation of 21 U.S.C. §§ 331(c) and 333(a)(2); introduction of unapproved drugs into interstate commerce in violation of 21 U.S.C. §§ 331(d) and 333(a)(2); and unlicensed wholesale distribution of prescription drugs in violation of 21 U.S.C. §§ 331(t), 333(b)(1)(D), and 355. He was sentenced principally to 60 months in prison.

The main issue on appeal is whether the district court properly excluded evidence relating to Scully’s advice-of-counsel defense. Because we find that the evidence was admissible and its exclusion was not harmless error, we VACATE the district court’s judgment and REMAND for further proceedings consistent with this decision. 1

BACKGROUND

The jury found Scully guilty of all charges relevant to this appeal, so we consider the evidence in the light most favorable to the government. See United States v. Bouchard, 828 F.3d 116, 120 (2d Cir. 2016).

1. The Rise and Fall of Pharmalogical

Scully and Shahrad Rodi Lameh founded Pharmalogical, Inc., in 2002 or 2003 as equal owners, Scully running the company’s day-to-day operations and Lameh managing payments and providing most of the capital. They initially planned to acquire pharmaceutical products from manufacturers and sell those products to retail customers (such as doctors, hospitals, and clinics) as a wholesale distributor, To that end, Pharmalogical received a license from New York State authorizing it to act as a wholesale distributor of pharmaceutical products. Pharmalogical struggled to turn a profit for several years, and eventually Scully decided to set the company on a new course: parallel importing. That is, rather than buying prescription drugs and medical devices approved by the U.S. Food and Drug Administration from the drug manufacturers, the company would import foreign versions of FDA-approved products into the United States from European distributors. Pharmalogical could purchase these drugs at reduced prices and then sell them to customers in the United States for far less than the going rate on the domestic market. Around the same time, the company also began doing business under the name Medical Deviee King or MDK.

Pharmalogical launched its parallel importing business around 2009 with purchases of Botox from a Canadian distributor. One of the company’s first potential customers, Dr. James Avellini, expressed concern that the product labels did not include a National Drug Code (“NDC”) 2 and requested assurances of the product’s legitimacy before he placed an order. Dr. Avellini’s inquiry prompted Scully and La-meh to approach an attorney, Richard Gertler, then of Thaler & Gertler, LLP, to research whether it was legal to resell the imported products in the United States. Gertler produced an opinion letter dated May 27, 2009, indicating that “Pharmalogical has not received any correspondence or notification from the FDA advising that Pharmalogical is operating in violation of any of the provisions of the Federal Food, Drug and Cosmetic Act,” and that “Phar-malogical has no reason to believe that it is not in full compliance with the FFDCA or any other statute or regulation.” App’x 400. The letter satisfied Dr, Avellini and others that Pharmalogical was authorized to sell Botox.

Scully and Lameh soon learned that the Canadian distributor with which they had been placing Botox orders simply forwarded those orders to a European distributor, which then shipped the product to Phar-malogical in the United States. Pharma-logical decided to cut out the Canadian middleman and began to place orders for Botox and a second product, Mirena intrauterine devices, directly with the European company. They also began buying Mirena IUDs at an even lower price from a Turkish company that sold the devices with Finnish- and Turkish-language labels and packaging. Around that time, the FDA responded to an inquiry from Scully regarding the sale of the Mirena IUDs, notifying him that foreign-made versions of FDA-approved drugs were considered unapproved new drugs. Scully and Lameh asked Gertler to look into the matter and Gertler once again produced an opinion letter, finding that “the importation of Mirena ... • from Finland to the United States by Pharmalogical, Inc., for resale to the end user, would not violate the criminal laws of the United States.” App’x 417.

As had occurred with Botox, when a potential customer for the Mirena IUDs, Planned Parenthood, requested assurances that the product was lawful to purchase, Scully and Lameh provided Gertler’s Mire-na letter. Planned Parenthood then placed a small order for Mirena IUDs, but then rejected and returned the order because the product labels were missing NDCs. SCully and' Lameh nevertheless resolved to continue selling the Mirena IUDs to doctors. As the company’s sales of Botox and Mirena IUDs increased, Scully and Lameh further expanded their business into oncology products. Gertler did not issue a separate legal opinion regarding Pharmalogical’s importation and sale of oncology drugs.

The first signs of trouble for Pharmalogical came in May 2012, when FDA agents executed warrants to search Pharmalogical’s offices. In response, Gertler and other lawyers, including Peter Tomao for Scully and Geoffrey Kaiser for Lameh, arranged meetings with prosecutors, and Pharma-logical- ceased selling oncology products.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
877 F.3d 464, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-scully-ca2-2017.